HALO logo
halo search icon
SpyGlass Pharma, Inc.

US$21.89

Price Change Indicator
0.69 (3.26%)
SpyGlass Pharma, Inc.
SGP · NAS

SpyGlass Pharma, Inc.

Start Trading SGP for Free

US$21.89

Price Arrow0.69 (3.26%)
20/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusBig CandleHALO AllHALO Consensus ValueHammer BearishHammer Bearish (Realtime)Recent Earnings downgrade
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

SpyGlass Pharma, Inc. Overview

SGP Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About SGP

icon

Website

SpyGlass Pharma, Inc.

icon

Telephone

1.949.284.6904

icon

Address

Suite 100, 27061 Aliso Creek Road, Aliso Viejo, CA 92656

Description

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.

SGP Price Chart

Key Stats

Market Cap

US$708.79M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 20.15 - 32.44

Trade Value (12mth)

US$212,121.00

1 week

-8.66%

1 month

-13.29%

YTD

-19.7%

1 year

0%

All time high

32.44

Key Fundamentals

EPS 3 yr Growth

N/A

EBITDA Margin

0.00%

Operating Cashflow

-$33m

Free Cash Flow Return

-53.30%

ROIC

-64.90%

Interest Coverage

0.00

Quick Ratio

12.70

Other Data

Shares Outstanding (Fully Diluted)

20m

HALO Sector

Healthcare

Next Company Report Date

26-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

SGP Announcements

Latest Announcements

DateAnnouncements
15 May 26
15 May 26
15 May 26
27 March 26
27 March 26

SGP Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
 $locklocklocklock-0.42-0.91-1.19locklocklock
EPS (Fully Diluted)
 $locklocklocklock-0.42-0.91-1.19locklocklock
Growth
 %locklocklocklockN/A-119-30.5locklocklock
PE
 XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
 XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of SpyGlass Pharma, Inc. (SGP:NAS)?
Halo FAQ
The current share price of SpyGlass Pharma, Inc. (SGP:NAS) is USD$21.89.
What is the 52-week high share price for SpyGlass Pharma, Inc. (SGP:NAS)?
Halo FAQ
The 52-week high share price for SpyGlass Pharma, Inc. (SGP:NAS) is USD$32.44.
What is the 52-week low share price for SpyGlass Pharma, Inc. (SGP:NAS)?
Halo FAQ
The 52-week low share price for SpyGlass Pharma, Inc. (SGP:NAS) is USD$20.15.
What is the dividend yield for SpyGlass Pharma, Inc. (SGP:NAS)?
Halo FAQ
SpyGlass Pharma, Inc. (SGP:NAS) does not pay a dividend.
What was SpyGlass Pharma, Inc. (SGP:NAS) last dividend payment?
Halo FAQ
SpyGlass Pharma, Inc. (SGP:NAS) does not pay a dividend.
What is the franking level for SpyGlass Pharma, Inc. (SGP:NAS)?
Halo FAQ
SpyGlass Pharma, Inc. (SGP:NAS) has a franking level of 0.00%.
In which sector is SpyGlass Pharma, Inc. (SGP:NAS) classified?
Halo FAQ
SpyGlass Pharma, Inc. (SGP:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial